ABL BIO
ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. Their core values are life-improvement, collaboration, innovation and novel therapy.
ABL BIO
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.ablbio.com
Total Employee:
11+
Status:
Active
Contact:
(82)10-9191-5219
Total Funding:
90.81 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Google Tag Manager Google Universal Analytics Apache Global Site Tag Mobile Non Scaleable Content Euro
Similar Organizations
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Employees Featured
Founder
Investors List
DS Asset Management
DS Asset Management investment in Series C - ABL Bio
Alpen Route Asset Management
Alpen Route Asset Management investment in Series C - ABL Bio
QUAD Investment Management
QUAD Investment Management investment in Series C - ABL Bio
Hana Financial Investment
Hana Financial Investment investment in Series C - ABL Bio
DSC Investment
DSC Investment investment in Series B - ABL Bio
Global Bio Growth First Private Equity Investment
Global Bio Growth First Private Equity Investment investment in Series B - ABL Bio
Korea Investment Securities
Korea Investment Securities investment in Series B - ABL Bio
Korea Investment Partners
Korea Investment Partners investment in Series B - ABL Bio
HantuPa
HantuPa investment in Series A - ABL Bio
DSC Investment
DSC Investment investment in Series A - ABL Bio
Official Site Inspections
http://www.ablbio.com Semrush global rank: 5.7 M Semrush visits lastest month: 1.47 K
- Host name: 175.106.98.22
- IP address: 175.106.98.22
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "ABL Bio"
ABL Bio
Our Core Values. ABL Bio is a research-led biotechnology company, a pioneer in bispecific antibodies for immuno-oncology and neurodegenerative diseases. Delivering new approaches to address the highest unmet needs, we are โฆSee details»
Pipeline - ABL Bio
Ablbio History. History of ABL Bio. 2024; 2023; 12. re-certified as Korea Innovative Pharmaceutical Company. 08. Most Promising Biologics Drug Pipeline (IMAPAC) 07. Paid-in capital increase allocated to a third party . 05. Article โฆSee details»
ABL Bio Inc. - LinkedIn
ABL Bio Inc. | 2,084 followers on LinkedIn. A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. | ABL Bio Inc. (Kosdaq: 298380) is a โฆSee details»
ABL Bio - Crunchbase Company Profile & Funding
ABL Bio is a biotech research company that focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.See details»
ABL BIO INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ABL BIO INC. of Seongnam, Gyeonggi. Get the latest business insights from Dun & Bradstreet.See details»
ABL Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Mar 7, 2025 www.ablbio.com. Public Company | 2016 | Gyeonggi-do, South Korea | 100-250 | KRX: 298380 | www.ablbio.com. Last update 07 Mar 2025. Overview. Pipeline. Deal. โฆSee details»
ABL Bio - app.biopharmiq.com
About: ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our โฆSee details»
ABL Bio - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 25, 2025 ABL Bio - Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases. Public Company. Raised a total funding of $65M โฆSee details»
ABL Bio
Ablbio media. ์์ด๋น์๋ฐ์ด์ค, aacr์ ์ ํ์ํ๊ณผ yh32364(abl104) ํฌ์คํฐ ๋ฐํ . ์์ด๋น์๋ฐ์ด์ค ํํธ๋์ฌ ์ฌ๋ ธํผ, ad/pd 2025์ abl301 ๋น์์ ๋ฐ์ดํฐ ๋ฐํ . ์์ด๋น์๋ฐ์ด์ค, ์จใ์คํ๋ผ์ธ โฆSee details»
ABL Bio
Ablbio medicine for a better Life South Korea's no.1 in bispecific antibody technology Outstanding R&D Personnel New Business Model through open innovation Innovation platforms & โฆSee details»
ABL Bio - Craft
ABL Bio is a biotech research company focusing on the development of therapeutic drugs for immuno-oncology and neurodegenerative disease. It offers a range of bispecific antibody โฆSee details»
Abl Bio-Technologies Limited | Company Details - The Company โฆ
Dec 21, 2024 ablbio.com; Social Media . Corporate Identity Details. CIN/LLPIN. L52599TN1992PLC022340; Company No. 022340; Company Classification. ... Recent activity โฆSee details»
Lonza and ABL Bio Collaborate in the Development and โฆ
Apr 4, 2023 Sanghoon Lee, Chief Executive Officer, ABL Bio said: "This collaboration with Lonza, a world-leading contract development and manufacturing organization (CDMO), is โฆSee details»
GSK pens $2.5B pact for ABL's blood-brain barrier-bypassing tech
Apr 7, 2025 GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean companyโs tech to bypass the blood-brain โฆSee details»
Seoul based ABL Bio is emerging as a leader in bi-specific โฆ
Nov 22, 2024 Founder & CEO Sang Hoon Lee describes the science that sets ABL apart - namely IGF1R as a shuttle target to help its CNS programs pass the blood brain barrier, 4 โฆSee details»
ABL Bio Announces Grabody-B Brain Delivery Platform License โฆ
SEONGNAM, South Korea, April 7, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno โฆSee details»
Pipeline - ABL Bio
ABL501. Pipeline ABL501; Program Target PD-L1 x LAG-3; Disease Indication Solid Tumor; Development Stage Clinical Development (Phase 1) Summary ABL501 is a bispecific antibody โฆSee details»
WuXi Biologics and ABL Bio Enter an Exclusive Development and โฆ
Dec 3, 2018 For more information, check out www.ablbio.com. About WuXi Biologics WuXi Biologics (stock code: 2269.HK), a Hong Kong -listed company, is the only open-access โฆSee details»
ABL Bio nears โฉ1 tril. deal with global pharma firm, poised to โฆ
Jan 24, 2025 ABL Bio, a Korean biotech firm, is reportedly close to finalizing a landmark technology licensing agreement with a global pharmaceutical company. The deal, said to be โฆSee details»
Investors & Media - ABL Bio
2025-04-07 ablbio - ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bioโs Grabody-B โฆSee details»